Protalix Historical Income Statement
| PLX Stock | USD 1.69 0.03 1.81% |
Historical analysis of Protalix Biotherapeutics income statement accounts such as EBIT of 11 M, Ebitda of 12.2 M, Total Operating Expenses of 25 M or Income Before Tax of 9 M can show how well Protalix Biotherapeutics performed in making a profits. Evaluating Protalix Biotherapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Protalix Biotherapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Protalix Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Protalix Biotherapeutics is a good buy for the upcoming year.
Protalix |
About Protalix Income Statement Analysis
Protalix Biotherapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Protalix Biotherapeutics shareholders. The income statement also shows Protalix investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Protalix Biotherapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Protalix Biotherapeutics. It is also known as Protalix Biotherapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Total Revenue
Total revenue comprises all receipts Protalix Biotherapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Protalix Biotherapeutics minus its cost of goods sold. It is profit before Protalix Biotherapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Net Income Applicable To Common Shares
The net income that remains after preferred dividends have been deducted, available to common shareholders.Most accounts from Protalix Biotherapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Protalix Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.At this time, Protalix Biotherapeutics' Selling And Marketing Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 28.1 M in 2024, whereas Interest Expense is likely to drop slightly above 2.8 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 38.4M | 47.6M | 65.5M | 68.8M | Depreciation And Amortization | 1.1M | 1.1M | 1.2M | 1.7M |
Protalix Biotherapeutics income statement Correlations
Click cells to compare fundamentals
Protalix Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Protalix Biotherapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 8.0M | 9.7M | 7.5M | 2.5M | 3.2M | 2.8M | |
| Selling General Administrative | 6.0M | 5.1M | 4.0M | 13.6M | 25.5M | 26.7M | |
| Other Operating Expenses | 65.4M | 60.2M | 58.8M | 60.7M | 55.0M | 31.5M | |
| Operating Income | (10.7M) | 1.8M | (20.5M) | (13.0M) | 10.5M | 11.0M | |
| Ebit | (10.7M) | 3.1M | (20.1M) | (11.9M) | 10.5M | 11.0M | |
| Ebitda | (8.7M) | 4.5M | (18.9M) | (10.8M) | 11.7M | 12.2M | |
| Total Operating Expenses | 54.5M | 49.3M | 42.5M | 41.1M | 32.1M | 25.0M | |
| Income Before Tax | (18.3M) | (6.5M) | (27.6M) | (14.4M) | 8.6M | 9.0M | |
| Total Other Income Expense Net | (7.6M) | (9.2M) | (7.1M) | (1.4M) | (1.9M) | (1.8M) | |
| Net Income | (26.2M) | (14.9M) | (34.0M) | (14.9M) | 8.3M | 8.7M | |
| Income Tax Expense | 8.0M | 8.4M | 6.4M | 530K | 254K | 241.3K | |
| Depreciation And Amortization | 2.0M | 1.3M | 1.1M | 1.1M | 1.2M | 1.7M | |
| Total Revenue | 54.7M | 62.9M | 38.4M | 47.6M | 65.5M | 68.8M | |
| Gross Profit | 43.8M | 52.0M | 22.0M | 28.0M | 42.5M | 44.6M | |
| Cost Of Revenue | 10.9M | 10.9M | 16.3M | 19.6M | 23.0M | 24.1M | |
| Selling And Marketing Expenses | 15.9M | 16.2M | 16.7M | 25.3M | 40.4M | 42.4M | |
| Research Development | 44.6M | 38.2M | 29.7M | 29.3M | 17.1M | 28.1M | |
| Net Income From Continuing Ops | (18.3M) | (6.5M) | (27.6M) | (14.9M) | 8.3M | 8.7M | |
| Net Income Applicable To Common Shares | (18.3M) | (6.5M) | (27.6M) | (14.9M) | (13.4M) | (14.1M) | |
| Net Interest Income | (7.6M) | (9.2M) | (7.1M) | (1.4M) | (1.9M) | (2.0M) | |
| Interest Income | 407K | 438K | 401K | 1.1M | 1.3M | 686.3K | |
| Reconciled Depreciation | 1.6M | 1.3M | 1.1M | 1.1M | 1.2M | 1.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.